Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$1.98 - $3.17 $37,576 - $60,160
-18,978 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$2.42 - $3.98 $15,601 - $25,659
6,447 Added 51.45%
18,978 $57,000
Q4 2021

Feb 14, 2022

BUY
$3.11 - $4.61 $38,971 - $57,767
12,531 New
12,531 $49,000
Q1 2020

May 15, 2020

SELL
$1.01 - $3.42 $19,870 - $67,285
-19,674 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$0.87 - $2.89 $17,116 - $56,857
19,674 New
19,674 $55,000
Q3 2019

Nov 14, 2019

SELL
$1.34 - $2.4 $210,782 - $377,520
-157,300 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$1.46 - $4.44 $229,658 - $698,412
157,300 New
157,300 $327,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $577M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Paloma Partners Management CO Portfolio

Follow Paloma Partners Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paloma Partners Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Paloma Partners Management CO with notifications on news.